| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| RYTM | RYTM | Shares | USD | XNMS |
| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| RYTM | RYTM | Shares | USD | XNMS |
Rhythm Pharmaceuticals, Inc. develops precision medicines for patients with rare neuroendocrine diseases, focusing on conditions related to the melanocortin-4 receptor (MC4R) pathway. Its lead product, IMCIVREE® (setmelanotide), is FDA-approved for treating severe obesity due to POMC and LEPR deficiencies, as well as Bardet-Biedl syndrome (BBS). The company conducts clinical trials to advance its therapies and operates primarily in North America and Europe.
No recent RNS announcements for RYTM across RYTM.
No recent RNS announcements for RYTM across RYTM.